AZ divests Movantik rights to RedHill
The divestment is expected to complete in the first quarter of 2020, subject to customary closing conditions and regulatory clearances.
Read More
Tag: Nektar
BMS, Nektar to jointly develop, commercialise immunotherapy combo
Bristol-Myers Squibb and Nektar Therapeutics have signed a deal to develop and commercialise the latter’s lead immuno-oncology programme, NKTR-214, in combination with other anticancer therapies, on the back of the success of a previous clinical trials pact.
Read More
Bayer/Nektar experimental inhaled antibiotic fails in Phase III
Bayer and Nektar Therapeutics’ experimental inhaled antibiotic has failed to hit key targets assessing its effect on survival in patients with Gram-negative pneumonia.
Read More
Lilly, Nektar to co-develop new immunotherapy
Eli Lilly and Nektar Therapeutics have signed a pact to co-develop the latter’s experimental immunotherapy NKTR-358 for a range of autoimmune and other chronic inflammatory conditions under a deal valued at $400 million.
Read More
BMS, Nektar to test immunotherapy combo in cancer
Bristol-Myers Squibb has signed a clinical trials pact with Nektar Therapeutics that will test a combination of the firms’ immunotherapy drugs across a range of cancer indications.
Read More
